Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ningetinib in Relapsed/Refractory AML
NCT03125876Phase 1Terminated
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ningetinib in acute myeloid leukemia (AML), sponsored by Sunshine Lake Pharma. Primary endpoint: Maximum Tolerated Dose. Started Nov 2017; status: terminated.
02
Drugs
ningetinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03125876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125876.